Structured Deal Surge Reshapes Venture Capital Term Sheets

When a Series C company in the enterprise AI space closed a $180 million round in late March, the press release mentioned the new lead investor, the expanded total addressable market, and the usual boilerplate about accelerating product development. What it did not mention was the 2x liquidation preference with a 3x participation cap, a board seat pledged to the lead as a protective provision, and a pay-to-play clause that forced three existing investors to either put in their pro-rata or watch their preferred stock convert to common. The round was priced at a 22% discount to the company's 2024 peak valuation. The founders signed anyway.

That round is not an outlier. According to the Cooley Q1 2026 Venture Financing Report, deal volume across the 165 reported transactions Cooley handled fell to its lowest level since Q3 2016, even as $39.9 billion was deployed — a concentration of capital into fewer, more carefully structured deals. Median pre-money valuations trended upward, and up rounds reached 86%, which looks healthy on a bar chart. But the same data set conceals what the term sheets actually say.

The phrase "structured deal" has a history in venture capital that is mostly unglamorous. It used to mean a down round with a ratchet — the kind of thing a GP would whisper about at a Limited Partner annual meeting but never feature in a blog post. What is changing is not just the frequency of these terms but their normalization across stages. Associates at two major Valley firms described a recent seed extension where the lead demanded a 1.5x participating preferred with no cap — a structure that, five years ago, would have been laughed out of a Sand Hill Road conference room. The founder took it because the alternative was a bridge loan from insiders at an 18% interest rate and warrants that would have been more dilutive on conversion.

To understand why structured deals are proliferating now, you have to look at who is writing the checks and what they need to show their own LPs. The 2023–2025 vintage of venture funds raised in an environment where institutional allocators were already questioning the 2021 mark-ups. Now those same allocators are reading the public markets. When T. Rowe Price Group reported its Q1 2026 earnings on May 2, executives highlighted improving earnings and continued progress in exchange-traded funds and separately managed accounts — but the subtext for the venture industry is that a public asset manager of T. Rowe's scale, with significant exposure to private markets through its alternatives platform, is under pressure to demonstrate that its illiquid holdings are marked responsibly. That pressure flows downstream.

T. Rowe Price is not merely an LP in a handful of brand-name funds. It is one of the largest allocators to venture capital globally, with commitments spanning seed-stage micro-funds to late-stage crossover vehicles. When the firm's alternatives team reviews fund performance, it is scrutinizing not just the internal rate of return but the structural protections embedded in the underlying portfolio company term sheets. A fund that deployed capital into plain-vanilla 1x non-participating preferred in 2024 and is now marking those positions against down rounds looks worse on a risk-adjusted basis than a fund that negotiated a 2x liquidation preference and a weighted-average anti-dilution provision. The LP relations team at every major VC firm knows this math.

What the LP community wants right now is not just return — it's return with a floor. Structured terms are the floor.— A fund-of-funds analyst at a Northeast endowment, speaking on background

The mechanics themselves are worth walking through, because the vocabulary obscures how the economics actually shift. A participating preferred stock allows the investor to receive its liquidation preference first — say, 2x its original investment — and then participate pro-rata in the remaining proceeds as if it held common stock. Without a cap, that can mean an investor who put in $50 million at a $200 million post-money valuation can walk away with $100 million off the top in a $150 million exit before common shareholders see a dollar. Caps — typically 2x to 4x the original investment — limit the double-dip, but the cap is a negotiation point, not a given. In three of the five structured rounds I reviewed for this piece, the cap was set at 3x, which still leaves founders and employees diluted far beyond what the headline valuation implies.

Full-ratchet anti-dilution is the provision that makes even seasoned founders flinch. If a company raises a down round, a full ratchet reprices the existing preferred stock to the new, lower price per share — as if the prior round had never happened at the higher valuation. This creates a massive transfer of ownership from common shareholders (founders, employees, early investors who did not participate) to the later-stage preferred holders who negotiated the ratchet. Weighted-average anti-dilution, which adjusts the conversion price based on the size and price of the new round, is more common and less punitive, but full ratchets have been appearing in growth-stage deals where the lead investor has leverage — specifically, where the company has fewer than six months of runway and the existing syndicate is unwilling to bridge.

Pay-to-play provisions add a behavioral layer. In a pay-to-play round, existing investors who do not participate in the new financing — at least to their pro-rata share — lose some or all of their preferential rights. Their preferred stock converts to common, which means they lose their liquidation preference, their anti-dilution protection, and often their board seat rights. The hard version is automatic conversion for non-participants. The soft version — sometimes called a "pull-through" — merely strips anti-dilution protections.

Redemption rights are the sleeper provision that most founders overlook during negotiation because the exercise date feels abstract. A redemption right allows preferred shareholders to demand that the company repurchase their shares at the original purchase price — or at a premium — after a specified period, typically five to seven years from the investment date. If the company has not exited or gone public by then, the investor can trigger a redemption. In practice, redemptions are rare because a company that cannot exit also cannot fund a buyback, but the threat reshapes the boardroom dynamic. It gives the preferred investor a lever to force a sale, a merger, or a recapitalization on a timeline that the founders may not control.

What makes the current wave distinctive is that structured terms are migrating from distressed situations to growth-stage and even early-stage rounds where the company is performing well on operating metrics. The reason is capital supply. Venture dollars are concentrating into a smaller number of firms, and those firms are writing larger checks with more conditions. The Crunchbase data on fintech funding in Q1 2026 showed more money going into far fewer deals, a pattern that holds across sectors. When a founder has one credible term sheet instead of five, the negotiating leverage shifts dramatically. The structured terms that would have been dealbreakers in 2021 are now table stakes.

The public markets are running a parallel experiment, and venture investors are watching it closely. Michael Saylor's Strategy — the Bitcoin treasury company formerly known as MicroStrategy — told investors in February that it faces no liquidation risk unless Bitcoin falls to roughly $8,000, a disclosure that came amid a flurry of structured-equity issuance including convertible notes and the controversial 11% dividend Perpetual Stretch Preferred Stock (NASDAQ: STRC). The STRC preferred carries features that would look familiar to any growth-stage VC: a fixed dividend obligation, a liquidation preference, and structural seniority over common equity. The difference is that Strategy's preferred trades in the public market, where the price discovery is brutal and daily. As of late April, STRC was trading below its $100 par value, a signal that public investors are repricing the embedded optionality in real time. Venture capital preferred stock, by contrast, gets marked to model quarterly, and the marks lag reality by months.

Saylor's structured-equity playbook — convertible notes that convert at a premium, at-the-market equity programs, preferred stock with cumulative dividends — is essentially a venture capital term sheet blown up to public-company scale. The difference in transparency is instructive. When Strategy issues a convertible note, the conversion price, the maturity date, and the interest rate are all filed with the SEC within days. When a unicorn issues a convertible note in a private round, those terms may not leak for months, if ever, and the employees holding common stock rarely understand what the note implies for their own equity until the next financing round reprices the cap table.

The lawyers who draft these documents are seeing the shift in real volume. At Cooley, the Q1 report noted that terms like cumulative dividends on preferred — once a rarity outside of life sciences deals — appeared in a growing fraction of the reported transactions. Fenwick & West and Gunderson Dettmer, the other two firms that dominate venture deal work, have not yet published their Q1 numbers. The goal is to make a full ratchet as routinized as a one-year cliff for founder vesting. That goal itself is a sign of where the market is heading.

One structural question that divides GPs is whether the proliferation of structured terms is a cyclical response to the 2022–2024 correction or a permanent shift in the risk-reward architecture of venture capital. The cyclical argument is straightforward: when the Federal Reserve cut rates in 2024 and 2025, growth-stage capital became more expensive relative to the zero-rate era, and investors demanded more protection. When the next bull market arrives, the argument goes, terms will revert to founder-friendly norms. The structural argument is that the LP community has seen what happens when terms are too loose — the 2021 vintage of mega-rounds produced paper mark-ups that turned into real write-downs — and will not fund the next cycle without embedded protections, regardless of the macro environment.

I lean toward the structural view, for one reason: the people who sit on investment committees at endowments, pension funds, and sovereign wealth funds rotate slowly, and institutional memory runs deep. The same allocators who absorbed the 2022–2023 NAV markshare are now writing the investment policy statements that govern commitments to the 2026 and 2027 vintages. Those policy statements increasingly include explicit language about downside protection, liquidity preferences, and governance rights. A GP who pitches a 2026 fund with a slide deck full of 1x non-participating preferred rounds is answering a question the LP already asked in the diligence questionnaire. The structured deal is not a fad. It is the new underwriting standard.

The downstream implications for founders and employees are significant and under-discussed. A 2x participating preferred with a 3x cap, layered on top of an earlier 1.5x preference from the Series B, can mean that a $400 million exit — objectively a strong outcome by any historical measure — returns zero dollars to common shareholders. The founders get nothing but the earn-out. The employees, whose stock options have strike prices set at the 2021 valuation, are underwater. The acqui-hire value is the only thing left. This is not a hypothetical; it is the exit math for at least two unicorns that are currently running dual-track processes — one track for a sale, the other for a structured down round — with the board preferring the down round because it preserves the preferred stack.

The acquirers, for their part, have learned to read term sheets as carefully as the investors. Corporate development teams at the major tech platforms now model the liquidation stack before they make an offer. If the preferred overhang exceeds the acquisition price, the deal does not close unless the preferred investors agree to a cramdown — a negotiated reduction of their preferences to allow some proceeds to flow to common and to the retention packages that keep key employees from walking. Those cramdown negotiations are happening more frequently, and they are a direct consequence of structured terms that were negotiated in a different capital-market environment.

Not every structured deal is a distress signal. There is a category of structured equity — revenue-based preferred, convertible equity with valuation caps, and shared-appreciation rights — that genuinely aligns investors and founders in a way that traditional preferred does not. These instruments, pioneered by firms like Earnest Capital and revived in the current cycle by a handful of emerging managers, tie investor returns to actual cash flows rather than to exit valuations. The Cooley data does not track these separately, but conversations with platform staff at three firms suggest that revenue-linked structures are gaining traction in vertical SaaS and climate-hardware deals where the exit path is uncertain but the unit economics are strong.

The broader financial ecosystem is also taking cues from the structured-deal playbook in ways that fall outside the venture capital lens but are worth noting. The UK homebuilder Vistry Group reported full-year 2025 profit before tax in line with expectations in March, supported by what management described as a "very, very strong" land acquisition pipeline — a pipeline that has been financed, in part, through structured joint ventures where capital partners receive preferred returns and downside protection before the developer takes its promote. The same structural logic — senior capital with a preferred return, junior capital that gets the upside after the hurdle — is migrating across asset classes, and venture capital is neither immune from it nor particularly sophisticated in its application compared to real estate or infrastructure.

The question I get most often from founders who are facing a structured term sheet for the first time is whether they should walk away. The answer depends on the alternative. If the alternative is a clean 1x non-participating round from a credible lead at a valuation that works, then walking away is rational — but that alternative is not available to most companies right now. If the alternative is a bridge loan from insiders at punitive terms, or a sale process with no obvious buyer, then the structured round is the least bad option, provided the founder negotiates the cap, the ratchet, and the pay-to-play trigger with legal counsel who has done this before. Not all counsel have. The structured-deal playbook is concentrated in a small number of law firms, and founders who go in with general corporate counsel are at a negotiating disadvantage.

By this time next year, we will have two quarters of Fenwick and Gunderson data to compare against Cooley's Q1 benchmark, and the trend line will either be steeper or flatter. What to watch for: whether the 86% up-round figure holds into Q2 and Q3, and whether the concentration of structured terms remains in the growth stage or seeps further into Series A. If it seeps, the next generation of founders will learn to read a liquidation stack before they learn to read a board deck. Some of them already are.